Clinical Data Topline results from the Phase 1 SURPASS trial (data cut-off August 2, 2021)Emerging efficacy and durability data are promising with responses in five solid tumor indications
As of the data cut-off date, 25 patients had received the next-generation cell therapy, ADP-A2M4CD8, in the Phase 1 SURPASS trial, 22 patients were evaluable for efficacy with at least one post-baseline scan meeting the ≥4-week duration for evaluation of stable diseaseAll patients had advanced metastatic disease and had received multiple prior regimens of systemic therapy (median: 3; range 1-6)The overall response rate was 36% and the disease control rate was 86%There was a complete response reported in a patient with ovarian cancer, which remains ongoing at 6 months post‑infusion (data on file at Adaptimmune)Initial durability is encouraging. As of the data cut-off, 11 patients remain on study. Of the 8 responders, 5 remain in response with some remaining progression free >24 weeks